Product News

Share this article:

FDA approved labeling changes on Vyvance, Shire's ADHD drug, extending the product's efficacy to 13 hours in children 6 to 12. According to a Shire release, the label changes represent the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients including in the labeling. Consumer and professional campaign materials in support of the label changes are currently in the works, according to a spokesperson.


Bayer Diabetes Care launched a new A1C monitor – A1CNow Selfcheck – enabling people with diabetes to check their A1C level at home. The product is now available without a prescription, and provides at-home results within five minutes, according to a statement.

 

Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.